心血管植入式电子设备在亚临床心房颤动检测与治疗中的作用:综述
本综述探讨亚临床心房颤动(AF)的无症状、短时程特点及其与卒中风险的关系,指出当前卒中风险估计仅来自既往植入心血管植入式电子设备(CIED)的人群且差异大,口服抗凝治疗缺乏直接获益证据,尚无证据支持植入CIED检测AF或对检出者启动抗凝治疗有益。
要点
- 亚临床AF无症状、时程短,通常需长期连续监测发现。
- 卒中风险估计仅限既往CIED患者,风险比范围0.87至9.40。
- 尚无证据支持植入CIED检测AF或对检出者启动口服抗凝有益。
核心结论
- 目前无证据表明植入CIED检测AF或对检出AF者启动口服抗凝治疗有益。
- 正在和未来的研究将识别亚临床AF高危人群并评估口服抗凝的疗效、安全性和经济价值。
研究设计与样本
- 综述,基于现有研究总结亚临床AF的检测与治疗证据。
主要发现
- 亚临床AF无症状、时程短,通常通过长期连续监测检测。
- 卒中风险估计仅来自既往植入CIED的人群,风险比范围0.87(95%CI 0.58-1.31)至9.40(95%CI 1.80-47.00)。
- 亚临床AF的卒中风险 pathogenesis 可能包括近因因果因素、上游风险激活因素和风险标志物。
- 口服抗凝治疗可能是有用的卒中预防策略,但该人群无直接获益证据。
- 两项正在进行的试验将评估既往植入CIED且无临床AF诊断的卒中高危患者使用非维生素K口服抗凝药的风险与获益。
关键数值与推荐
- 卒中风险比范围0.87(95%CI 0.58-1.31)至9.40(95%CI 1.80-47.00),仅基于既往CIED患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 当前卒中风险估计仅局限于既往植入CIED的患者,且范围差异大。
- 该人群无口服抗凝治疗直接获益证据。
- 若临床获益被证实,亚临床AF筛查和治疗的成本效益仍需额外研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Subclinical atrial fibrillation (AF) is associated with an increased risk for stroke. OBSERVATIONS: Subclinical AF is asymptomatic, short in duration, and usually detected with long-term, continuous monitoring. Most prior studies have explored its consequences using cardiovascular implantable electronic devices (CIEDs). Although current prevalence estimates are derived from study populations with prior CIEDs, 3 trials will assess the time to a first AF diagnosis among patients receiving a CIED for purposes of AF detection. Stroke risk estimates are currently limited to patients with a prior CIED and vary widely, ranging from a hazard ratio of 0.87 (95% CI, 0.58-1.31) to 9.40 (95% CI, 1.80-47.00). Stroke risk pathogenesis may include factors that are proximately causal, upstream risk activators, and risk markers. The treatment of subclinical AF may be a useful stroke prevention strategy; however, no direct evidence of benefit from oral anticoagulation exists in this population. Two ongoing trials will assess the risk and benefit of non-vitamin K oral anticoagulants among patients at high risk for stroke with a previously placed implantable CIED, but without a prior diagnosis of clinical AF. If clinical benefit is proven, then the cost-effectiveness of screening for and the treatment of subclinical AF will require additional study. CONCLUSIONS AND RELEVANCE: At present, no evidence suggests that implanting a CIED to detect AF or initiating oral anticoagulation therapy among those in whom AF is detected is beneficial. Ongoing and future studies will identify people at high risk for developing subclinical AF and will evaluate the efficacy, safety, and economic value of oral anticoagulation therapy in this population.
引用
- Hess PL, Healey JS, Granger CB, et al. The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review. JAMA Cardiol. 2017. PMID: 28097334. doi:10.1001/jamacardio.2016.5167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。